Overview: Lambda Light Chain Immunohistochemistry TestIntroduction: The Lambda Light Chain Immunohistochemistry Test detects lambda light chains to diagnose multiple myeloma, causing bone pain or fatigue. Aligned with 2023 NCCN guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected multiple myeloma.
Other Names: Lambda IHC Assay, Multiple Myeloma IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Lambda light chain testing began in the 1980s with myeloma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects lambda light chains to diagnose multiple myeloma, guides treatment, and evaluates patients with bone pain or fatigue.
Test Parameters: 1. Lambda Light Chains
Pretest Condition: No fasting required. Collect tissue via bone marrow biopsy. Report history of bone pain, fatigue, or renal issues.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document bone pain, fatigue, renal issues, or family history of multiple myeloma. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, myeloma implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect lambda light chains in bone marrow tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for myeloma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive lambda staining suggests multiple myeloma, guiding chemotherapy or transplant. Negative staining may require kappa light chain testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Kappa IHC, serum free light chains, or bone marrow biopsy to confirm multiple myeloma diagnosis.
Test Limitations: Not specific to multiple myeloma; other plasma cell disorders may express lambda chains. Clinical correlation is needed.
References: NCCN Multiple Myeloma Guidelines, 2023; Blood, Kyle RA, 2022.
